About: More targeted use of oseltamivir and in-hospital isolation facilities after implementation of a multifaceted strategy including a rapid molecular diagnostic panel for respiratory viruses in immunocompromised adult patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: More targeted use of oseltamivir and in-hospital isolation facilities after implementation of a multifaceted strategy including a rapid molecular diagnostic panel for respiratory viruses in immunocompromised adult patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	More targeted use of oseltamivir and in-hospital isolation facilities after implementation of a multifaceted strategy including a rapid molecular diagnostic panel for respiratory viruses in immunocompromised adult patients
Creator	Riezebos-Brilman, Annelies Oosterheert, Jan Hoepelman, Andy Kaasjager, Karin Vos, Laura Weehuizen, Jesper
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Immunocompromised adults are more vulnerable to a complicated course of viral respiratory tract infections (RTI). OBJECTIVES: Provide evidence on the effect of implementation of rapid molecular diagnostics for viruses on use of in-hospital isolation facilities, oseltamivir and antibiotic usage, and other clinical outcomes in immunocompromised patients. STUDY DESIGN: A before-after study during two consecutive respiratory viral seasons, including immunocompromised adult patients presenting at a tertiary care emergency department with clinical suspicion of RTI. During the first season (2016/2017), respiratory viruses were detected using inhouse real-time PCR. The second season (2017/2018), we implemented a diagnostic flowchart including a rapid molecular test for 15 respiratory viruses (FilmArray®). We assessed the effect of this implementation on need for isolation, antivirals and empirical antibiotics. RESULTS: We included 192 immunocompromised adult patients during the first and 378 during the second season. Respiratory viral testing was performed in 135 patients (70%) during the first and 284 (75%) during the second season (p = 0.218) of which 213 (75%) using the rapid test. After implementation, use of in-hospital isolation facilities was reduced (adjusted odds ratio 0.35, 95%CI 0.19-0.64). Furthermore, adequate use of oseltamivir improved, with fewer prescriptions in influenza negative patients (0.15, 95%CI 0.08-0.28) and more in influenza positive patients (11.13, 95%CI 1.75–70.86). No effect was observed on empirical antibiotic use, hospital admissions, length of hospital stay or safety outcomes. CONCLUSIONS: Implementation of rapid molecular testing for respiratory viruses in adult immunocompromised patients results in more adequate use of oseltamivir and in-hospital isolation facilities without compromising safety.
has issue date	2019-04-07(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2019.04.003
bibo:pmid	30999234
has license	no-cc
sha1sum (hex)	d5896010c0e29c9cfb0c8403ab75f344a359769f
schema:url	https://doi.org/10.1016/j.jcv.2019.04.003
resource representing a document's title	More targeted use of oseltamivir and in-hospital isolation facilities after implementation of a multifaceted strategy including a rapid molecular diagnostic panel for respiratory viruses in immunocompromised adult patients
has PubMed Central identifier	PMC7185605
has PubMed identifier	30999234
schema:publication	J Clin Virol
resource representing a document's body	covid:d5896010c0e29c9cfb0c8403ab75f344a359769f#body_text
is schema:about of	named entity 'PATIENTS' named entity 'tertiary care' named entity 'testing' named entity 'season' named entity 'MOLECULAR' named entity 'SUSPICION' named entity '0.35' named entity 'RAPID' named entity 'ADULTS' named entity 'COURSE' named entity 'CONCLUSIONS' named entity 'EMERGENCY DEPARTMENT' named entity 'REDUCED' named entity 'MOLECULAR' named entity 'STUDY DESIGN' named entity 'ANTIBIOTIC USE' named entity 'RESULTS' named entity 'BACKGROUND' named entity 'ANTIBIOTICS' named entity 'TERTIARY CARE' named entity 'INFLUENZA' named entity 'OSELTAMIVIR' named entity 'ADULT' named entity 'HOSPITAL' named entity 'ISOLATION' named entity 'IMPLEMENTED' named entity 'ISOLATION' named entity 'REAL-TIME PCR' named entity 'HOSPITAL ADMISSIONS' named entity 'RTI' named entity 'EFFECT' named entity 'RESPIRATORY VIRUSES' named entity '0.19' named entity 'ADULT' named entity '135' named entity 'USE OF' named entity 'RESPIRATORY VIRUSES' named entity 'IMPLEMENTATION' named entity 'IMMUNOCOMPROMISED' named entity 'MULTIFACETED' named entity 'INCLUDING' named entity 'DIAGNOSTIC' named entity 'FACILITIES' named entity 'OSELTAMIVIR' named entity 'PANEL' named entity 'RAPID' named entity '0.08' named entity 'OBSERVED' named entity 'ANTIVIRALS' named entity 'VIRUSES' named entity 'CONSECUTIVE' named entity 'HOSPITAL' named entity '218' named entity 'NEED FOR ISOLATION' named entity 'ANTIBIOTIC' named entity 'OUTCOMES' named entity 'BEFORE-AFTER STUDY' named entity 'VULNERABLE' named entity 'NEGATIVE' named entity 'CLINICAL' named entity 'ADEQUATE' named entity 'NO EFFECT' named entity '0.64' named entity 'USAGE' named entity 'IMMUNOCOMPROMISED' named entity 'SAFETY' named entity 'TESTING WAS PERFORMED' named entity 'LENGTH OF HOSPITAL STAY' named entity 'SEASONS' named entity 'IMPLEMENTATION' named entity 'EVIDENCE' named entity 'TARGETED' named entity 'STRATEGY' named entity 'PRESENTING' named entity 'USING' named entity 'IMPROVED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software